← Eichor
Condition: Advanced Or Recurrent Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Or Recurrent Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Phase 1 · 14 location(s) · Riboscience, LLC. · NCT05270213BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Phase 1 · 4 location(s) · Bio-Path Holdings, Inc. · NCT04196257Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Phase 1 · 15 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06816108A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
Phase 1 · 2 location(s) · Peking University · NCT06541639Advanced or Recurrent Solid Tumors Treated With SHetA2
Phase 1 · 1 location(s) · University of Oklahoma · NCT04928508NCCH2006/MK010 Trial (FORTUNE Trial)
Phase 2 · 7 location(s) · National Cancer Center, Japan · NCT04962867A Study of KC1036 in Patients with Advanced Solid Tumors
Phase 1 · 3 location(s) · Beijing Konruns Pharmaceutical Co., Ltd. · NCT04387916A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Phase 1/Phase 2 · 15 location(s) · Advenchen Laboratories, LLC · NCT07392736Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07022002A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma
Phase 2 · 35 location(s) · Day One Biopharmaceuticals, Inc. · NCT04775485Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom T
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04693468A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Phase 1/Phase 2 · 2 location(s) · Spago Nanomedical AB · NCT06184035CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S
Phase 1/Phase 2 · 39 location(s) · ModernaTX, Inc. · NCT05533697Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Phase 1 · 10 location(s) · EpimAb Biotherapeutics (Suzhou)Co., Ltd. · NCT05607498Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05059678Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Act
Phase 1 · 6 location(s) · Jun Zhou · NCT07584954A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Stingray Therapeutics · NCT06063681A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.